Get started
Author

Mark H Wansbrough-Jones

Observed names: M H Wansbrough-Jones, M WANSBROUGHJONES, M Wansbrough-Jones, M. H. WANSBROUGH-JONES, M. H. Wansbrough-Jones, M. Wansborough-Jones, M. Wansbrough-Jones, M.H. Wansbrough-Jones, M.H. Wansbrough-Jonesl, MH Wansbrough-Jones (19880448), Mark H. Wansbrough-Jones, Mark H. Wansbrough-jones, Mark H. Wansbrough‐Jones, Mark Wansbrough-Jones, Mark Wansbrough-jones, Mark Wansbrough‐Jones, Wansborough-Jones, M, Wansbrough-Jones M
Observed institutions: University of London, Guy's Hospital, National Institutes of Health, St George's Hospital, St Thomas' Hospital, St. George's University, St George's, University of London, King's College London, Komfo Anokye Teaching Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, Royal Tropical Institute, St George’s University Hospitals NHS Foundation Trust, Kwame Nkrumah University of Science and Technology, World Health Organization, Chelsea and Westminster Hospital, Mortimer Market Centre, King's College Hospital, Addenbrooke's Hospital, City St George's, University of London, Imperial College London, Lister Institute of Preventive Medicine
OpenAlex ID: A5028918213
Neglected tropical diseases
2009 · N. Feasey, M. Wansbrough-Jones, et al. · British Medical Bulletin · 824
PDF
Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans
2005 · S. Etuaful, B. Carbonnelle, et al. · Antimicrobial Agents and Chemotherapy · 240
Mycobacterium ulcerans disease.
2005 · Tjip S van der Werf, Ymkje Stienstra, et al. · Europe PMC (PubMed Central) · 204
Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy
2012 · Nicholas I. Paton, Ruth L. Goodall, et al. · JAMA · 163
Buruli ulcer: emerging from obscurity
2006 · Mark Wansbrough-Jones, Richard Phillips · The Lancet · 160
Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial
2020 · Richard O Phillips, Jérôme Robert, et al. · The Lancet · 114
PDF
Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment ofMycobacterium ulceransDisease
2010 · Fred Stephen Sarfo, Richard Phillips, et al. · Antimicrobial Agents and Chemotherapy · 112
Recent advances: role of mycolactone in the pathogenesis and monitoring ofMycobacterium ulceransinfection/Buruli ulcer disease
2015 · Fred Stephen Sarfo, Richard Phillips, et al. · Cellular Microbiology · 100
PDF
Sensitivity of PCR Targeting the IS 2404 Insertion Sequence of Mycobacterium ulcerans in an Assay Using Punch Biopsy Specimens for Diagnosis of Buruli Ulcer
2005 · R. Phillips, C. Horsfield, et al. · Journal of Clinical Microbiology · 90
Immunosuppressive Signature of CutaneousMycobacterium ulceransInfection in the Peripheral Blood of Patients with Buruli Ulcer Disease
2009 · Richard Phillips, Fred S. Sarfo, et al. · The Journal of Infectious Diseases · 87
Human Herpesvirus Infections. Clinical Aspects
1983 · M Wansbrough-Jones · Postgraduate Medical Journal · 76
Enzyme Activities and Properties of Lysosomes and Brush Borders in Jejunal Biopsies from Control Subjects and Patients with Coeliac Disease
1975 · T. J. Peters, J. R. Heath, et al. · Clinical Science · 75
In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans
2000 · H. S. Thangaraj, O. Adjei, et al. · Journal of Antimicrobial Chemotherapy · 72
Buruli ulcer disease: prospects for a vaccine
2009 · Kris Huygen, Ohene Adjei, et al. · Medical Microbiology and Immunology · 71
Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease
2013 · Richard O. Phillips, Fred S. Sarfo, et al. · Antimicrobial Agents and Chemotherapy · 67
Mycolactone Diffuses into the Peripheral Blood of Buruli Ulcer Patients - Implications for Diagnosis and Disease Monitoring
2011 · Fred S. Sarfo, Fabien Le Chevalier, et al. · PLoS neglected tropical diseases · 67
PDF
Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin.
1978 · P J Johnson, M H Wansbrough-Jones, et al. · BMJ · 67
PDF
Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load
2019 · Michael Frimpong, Bernadette Agbavor, et al. · PLoS neglected tropical diseases · 65
PDF
Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease
2014 · Fred S Sarfo, Richard O Phillips, et al. · BMC Infectious Diseases · 64
PDF
Pilot Randomized Double-Blind Trial of Treatment ofMycobacterium ulceransDisease (Buruli Ulcer) with Topical Nitrogen Oxides
2004 · R. Phillips, O. Adjei, et al. · Antimicrobial Agents and Chemotherapy · 64
Prevalence and genotype of hepatitis C virus infection in pregnant women and blood donors in Ghana
1998 · M.H. Wansbrough-Jonesl, E. Frimpong, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 63
Sensitivity of PCR Targeting Mycobacterium ulcerans by Use of Fine-Needle Aspirates for Diagnosis of Buruli Ulcer
2009 · R. O. Phillips, F. S. Sarfo, et al. · Journal of Clinical Microbiology · 60
PDF
Mucosal Kaposiʼs sarcoma following protease inhibitor therapy in an HIV-infected patient
1997 · A Weir, M Wansbrough-Jones · AIDS · 58
Detection of Mycolactone A/B in Mycobacterium ulcerans–Infected Human Tissue
2010 · Fred Stephen Sarfo, Richard O. Phillips, et al. · PLoS neglected tropical diseases · 51
PDF
Mycobacterium ulcerans disease; Buruli ulcer
1999 · Harry S. Thangaraj, Mark R.W. Evans, et al. · Transactions of the Royal Society of Tropical Medicine and Hygiene · 51
Works count: 122
Citation count: 4,185
H-index: 33
I10-index: 61
Year
Topic
Type